AstraZeneca Pharma India Limited — Others, 18-11-2024: Copy of Newspaper Publication

AstraZeneca Pharma India Limited has announced a board meeting to discuss the financial results for the quarter and half-year ended 30 September 2024. The company reported total income of ₹4,161.5 million, a net profit of ₹384.3 million after tax, and earnings per share of ₹15.37. Notably, the company has recorded provisions of ₹575.6 million related to the closure of its manufacturing site, which it plans to exit over the next 12 months. This strategic move may raise concerns about potential operational disruptions, but it also opens avenues for improving efficiency. Investor sentiment could lean towards a positive outlook given the profitability despite the impending site closure.